natgillin/translations-raw huggingface dataset:
§, electrocardiogram abnormal palpitations, bradycardia, supraventricular extrasystoles, tachycardia 
sindromdolgega QT§,nenormalen elektrokardiogram§,palpitacije,bradikardija,supraventrikularne ekstrasistole, tahikardija
Do not take Posaconazole AHCL if any of the above apply to you. 
Ne vzemite zdravila Posakonazol AHCL, če kaj od naštetega velja za vas.
Some patients have also reported feeling confused after taking Posaconazole AHCL, the frequency of this is not known. 
Nekateri bolniki so po jemanju zdravila Posakonazol AHCL poročali tudi o občutkuzmedenosti;pogostnosttegani znana.
You may feel dizzy, sleepy, or have blurred vision while taking Posaconazole AHCL, which may affect your ability to drive or use tools or machines. 
Vpliv na sposobnost upravljanja vozil in strojev Med jemanjem zdravila Posakonazol AHCL ste lahko omotični, zaspani ali imate zamegljen vid, kar lahko vpliva na vašo sposobnost upravljanja vozil in strojev.
Certain medicines may increase the risk of side effects of Posaconazole AHCL by increasing the amount of Posaconazole AHCL in the blood. 
Določena zdravila lahko povečajo tveganje zapojavneželenih učinkovzdravila Posakonazol AHCL, kerpovečajokoličinozdravilaPosakonazol AHCL vkrvi.
The other ingredients in the suspension are macrogolglycerol hydroxystearate, sodium citrate dihydrate, citric acid monohydrate, simeticone emulsion (containing polydimethylsiloxane, polyethylene glycol sorbitan tristearate, methylcellulose, silica gel, polyethylene glycol stearate, sorbic acid (E200), benzoic acid (E210) and sulfuric acid (E513)), xanthan gum (E415), sodium benzoate (E211), liquid glucose, glycerol (E422), titanium dioxide (E171), strawberry flavour (containing propylene glycol) and purified water. 
Pomožne snovi v suspenziji so makrogolglicerol hidroksistearat, natrijev citrat dihidrat, citronska kislina monohidrat, emulzija simetikona (vsebuje polidimetilsiloksan, polietilenglikol sorbitan tristearat, metilcelulozo, silikagel, polietilenglikol stearat, sorbinsko kislino (E200), benzojsko kislino (E210) in žveplovo kislino (E513)), ksantanski gumi (E415), natrijev benzoat (E211), tekoča glukoza,
Posaconazole increased Cmax and AUC of tacrolimus (0.05 mg/kg body weight single dose) by 121 % and 358 %, respectively. 
Takrolimus Posakonazolje povečal Cmaxtakrolimusa(enkratni odmerek0,05 mg/kg telesne mase)za121 %innjegovo
- infections in the mouth or throat area (known as “thrush”) caused by fungi called Candida, which were not previously treated. 
- okužb v predeluustaližrela(znanepodimenom“sor”),kijihpovzročagliva Candida in katerepredhodno še niso bile zdravljene.
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V. 
Omogočanamrečstalnospremljanjerazmerjamedkoristmiintveganjizdravila.Odzdravstvenihdelavcev se zahteva, da poročajo o katerem koli domnevnem neželenem učinku zdravila nanacionalnicenter za poročanje, ki je naveden v Prilogi V.
Patients with a low body weight (< 60 kg) are more likely to experience higher plasma concentrations of posaconazole and should be closely monitored for adverse events. 
Zato je bolnike, ki tehtajo več kot 120 kg, priporočljivo skrbno spremljati glede prebijajočih glivnih okužb.Bolniki z majhno telesno maso (< 60 kg) imajo večjo verjetnost za povečane koncentracije posakonazola v plazmi in jih je trebaskrbno spremljati glede neželenih učinkov.
Adrenal suppressive effects were observed in toxicity studies in rats and dogs at exposures equal to or greater than those obtained at therapeutic doses in humans. 
Vštudijahtoksičnosti na podganah in psih so opažali supresivne učinke na nadledvično žlezo pri izpostavljenostih, ki so bile enake ali večje od izpostavljenosti, dosežene s terapevtskimiodmerki pričloveku.
Study 1899 was a randomised, evaluator-blinded study of posaconazole oral suspension (200 mg three times a day) versus fluconazole suspension (400 mg once daily) or itraconazole oral solution (200 mg twice a day) in neutropenic patients who were receiving cytotoxic chemotherapy for acute myelogenous leukaemia or myelodysplastic syndromes. 
Študija1899 je bila randomizirana, za ocenjevalce slepa študija,kijeprimerjala uporabo peroralne suspenzije posakonazola (200 mg trikrat na dan) in suspenzije flukonazola (400 mgenkratnadan)aliperoralne raztopine itrakonazola (200 mg dvakrat na dan) pri bolnikih z nevtropenijo, ki so prejemalicitotoksično kemoterapijo zaradi akutne mieloične levkemije ali mielodisplastičnih sindromov.
Do not take Posaconazole AHCL - if you are allergic to posaconazole or any of the other ingredients of this medicine (listed in section 6). 
- če ste alergični na posakonazol ali katerokoli sestavino tega zdravila (navedeno v poglavju6).
pancreatitis, abdominal distension, enteritis, epigastric discomfort, eructation, gastrooesophageal reflux disease, oedema mouth 
pankreatitis, abdominalna distenzija, enteritis, nelagodje v epigastriju, spahovanje, gastroezofagealna refluksna bolezen,edem v ustih
Cases of elevated ciclosporin levels resulting in serious adverse reactions, including nephrotoxicity and one fatal case of leukoencephalopathy, were reported in clinical efficacy studies. 
V študijah klinične učinkovitosti so poročali o primerih povečane koncentracije ciklosporina, ki je povzročila resne neželeneučinke, vključno znefrotoksičnostjo in enim smrtnim primerom levkoencefalopatije.
Caution should be used when prescribing Posaconazole AHCL to patients with hypersensitivity to other azoles. 
Pri predpisovanju zdravila Posakonazol AHCL bolnikom, preobčutljivim na druge azole, je potrebna previdnost.
9 of 11 patients were successfully treated with posaconazole oral suspension 800 mg/day in divided doses for a median of 268 days and up to 377 days. 
9 od 11 bolnikov so uspešno zdravilis peroralno suspenzijo posakonazola 800 mg/dan v deljenihodmerkih.Srednjavrednosttrajanjazdravljenja jebila268 dni,zdravljenjepaje lahko trajalodo377 dni.
On the first day of treatment take 200 mg (one 5 mL spoonful) once. 
Prvi dan zdravljenja zaužijte enkrat 200 mg(eno polno 5 mlžličko).
There were fewer breakthrough Aspergillus infections in patients receiving posaconazole prophylaxis when compared to control patients. 
Med bolniki, ki so prejemaliprofilakso sposakonazolom, jebilo prebijajočih okužb z Aspergillusommanj kot med primerjalnimi bolniki.
vomiting, abdominal pain, diarrhoea, dyspepsia, dry mouth, 
bruhanje, bolečine v trebuhu, diareja, dispepsija, suha usta,
NAME OF THE MEDICINAL PRODUCT Posaconazole AHCL 40 mg/mL oral suspension 
IME ZDRAVILA Posakonazol AHCL 40 mg/ml peroralna suspenzija
The duration of therapy is based on recovery from neutropenia or immunosuppression. 
Trajanjezdravljenja je odvisno od okrevanja po nevtropeniji aliimunosupresiji.
Treatment with these HMG-CoA reductase inhibitors should be discontinued during treatment with posaconazole as increased levels have been associated with rhabdomyolysis (see section 4.3). 
Med zdravljenjem s posakonazolomjetrebazdravljenje z zaviralci reduktazeHMG-CoAprekiniti, ker so bile povečane koncentracije povezane z rabdomiolizo (glejte poglavje 4.3).
What you need to know before you take Posaconazole AHCL 
Kaj morate vedeti, preden boste vzeli zdravilo Posakonazol AHCL
Five of these patients had chromoblastomycosis due to Fonsecaea pedrosoi and 4 had mycetoma, mostly due to Madurella species. 
Petod teh bolnikov je imelo kromoblastomikozo zaradi okužbe sFonsecaea pedrosoi,
Always take this medicine exactly as your doctor or pharmacist has told you. 
Prijemanju tega zdravila natančno upoštevajte navodila zdravnika ali farmacevta.
Study 316 was a randomised, double-blind trial of posaconazole oral suspension (200 mg three times a day) versus fluconazole capsules (400 mg once daily) in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease (GVHD). 
Študija316 je bila randomizirano, dvojno slepo preskušanje s peroralno suspenzijo posakonazola(200 mgtrikrat na dan) v primerjavi s kapsulami flukonazola (400 mgenkratnadan)pri bolnikih poalogenskitransplantacijihematopoetskih matičnih celic zreakcijo presadka proti gostitelju
Posaconazole AHCL 40 mg/mL oral suspension posaconazole 
Posakonazol AHCL 40 mg/ml peroralna suspenzija posakonazol
pyrexia (fever), asthenia, fatigue 
pireksija, astenija, utrujenost
As a result, sirolimus trough concentrations that fall within the usual therapeutic range may result in sub-therapeutic levels. 
Zaradi tega lahko najnižja koncentracija sirolimusa, ki ješe vobičajnemterapevtskem razponu, dejansko pomeni koncentracijo,nižjo od terapevtske.
Whenever possible you should take posaconazole during or immediately after food or a nutritional drink. 
Čejele mogoče,posakonazol vzemite med ali takoj po jedi ali zaužitju prehranskega dopolnila vobliki napitka.
The microbiological data suggest that posaconazole is active against Rhizomucor, Mucor, and Rhizopus; however the clinical data are currently too limited to assess the efficacy of posaconazole against these causative agents. 
Rhizopus;vendar jekliničnih podatkovtrenutno premalo, da bi lahko ocenili učinkovitost posakonazola proti tem povzročiteljem okužb.
If you forget to take Posaconazole AHCL 
Če ste pozabili vzeti zdravilo Posakonazol AHCL
Posaconazole AHCL contains glucose 
Zdravilo Posakonazol AHCL vsebuje glukozo
Treatment of refractory Fungal Infections (Invasive aspergillosis, Fusariosis, 
Zdravljenje rezistentnih glivnih okužb (invazivna aspergiloza,fusarioza,kromoblas tomikoza/micetom, kokcidioidomikoza)
Posaconazole was shown to be non-inferior to fluconazole for clinical success rates at Day 14 as well as 4 weeks after the end of treatment. 
Za posakonazol so pokazali, da po klinični uspešnosti, ugotovljeni na 14. dan in 4tedne po koncu zdravljenja, ni nič slabši od flukonazola.
However, as posaconazole is not significantly renally eliminated, an effect of severe renal impairment on the pharmacokinetics of posaconazole is not expected and no dose adjustment is recommended. 
Ker pa seposakonazol skozi ledvice neizloča v pomembnimeri, ni pričakovati, da bi huda okvara ledvicvplivalana farmakokinetiko posakonazola;prilagajanje odmerka tako ni potrebno.Posakonazolseneodstranjuje s hemodializo.
Several of the interaction studies were conducted in healthy volunteers in whom a higher exposure to posaconazole occurs compared to patients administered the same dose. 
Pri zdravih prostovoljcih je bilo opravljenihvečštudij medsebojnega delovanjaposakonazola z drugimi zdravili, pri katerih jebila izpostavljenost posakonazolu večja kot pri bolnikih, ki so prejemali enakodmerek.
The effect of posaconazole on fosamprenavir levels when fosamprenavir is given with ritonavir is unknown. 
23 %.Vpliv posakonazola nakoncentracijo fosamprenavirja v primeru uporabe fosamprenavirja zritonavirjem ni znan.
In a study (Study 03579) of 136 neutropenic paediatric patients 11 months - 17 years treated with posaconazole oral suspension at doses up to 18 mg/kg/day divided TID, approximately 50% met the pre-specified target (Day 7 Cav between 500 ng/mL-2,500 ng/mL) (see section 5.2). 
Vštudiji(študija03579) pri 136 nevtropeničnih pediatričnih bolnikih, starih od 11 mesecevdo 17 let, zdravljenih s peroralno suspenzijo posakonazola v odmerkihdo 18 mg/kg/dan, razdeljenih na tri odmerke dnevno, je približno 50 % bolnikov doseglo vnaprejdoločen cilj (povprečna koncentracija v stanju dinamičnega ravnovesja (Cav) 7. dan med 500
This medicine can also be used to prevent fungal infections in adults who are at high risk of getting a fungal infection, such as: - patients who have a weak immune system due to having chemotherapy for “acute myelogenous leukemia” (AML) or “myelodysplastic syndromes” (MDS) - patients having “high- dose immunosuppressive therapy” after “hematopoietic stem cell transplant” (HSCT). 
Tozdravilo se lahko uporabitudiza preprečevanje glivnih okužb priodraslih, ki imajo velikotveganje za takšne okužbe, na primer: - pri bolnikih z oslabljenim imunskim sistemom zaradi kemoterapije, potrebne za zdravljenje akutne mieloične levkemije (AML) ali mielodisplastičnih sindromov (MDS);
Electrolyte disturbances, especially those involving potassium, magnesium or calcium levels, should be monitored and corrected as necessary before and during posaconazole therapy. 
Bolnika jetreba spremljati, da bi ugotovilimorebitne motnje ravnovesja elektrolitov, zlastimotnjekoncentracijekalija, magnezija ali kalcija, in jih po potrebi odpravitipred ali med zdravljenjem sposakonazolom.
Simeticone emulsion (containing polydimethylsiloxane, polyethylene glycol sorbitan tristearate, methylcellulose, silica gel, polyethylene glycol stearate, sorbic acid (E200), benzoic acid (E210) and sulfuric acid (E513)) 
6.1 Seznam pomožnih snovi makrogolglicerol hidroksistearat natrijevcitratdihidrat citronska kislina monohidrat emulzija simetikona (vsebuje polidimetilsiloksan, polietilenglikol sorbitan tristearat, metilcelulozo, silikagel, polietilenglikol stearat, sorbinsko kislino (E200), benzojsko kislino (E210) in žveplovo kislino (E513)) ksantanski gumi(E415) natrijev benzoat (E211)
However, the safety profile of posaconazole between the Black and Caucasian subjects was similar. 
Vendar pa jebilvarnostniprofilposakonazola pri preiskovancih črne in bele rase podoben.
- Oropharyngeal candidiasis: as first-line therapy in patients who have severe disease or are immunocompromised, in whom response to topical therapy is expected to be poor. 
ter pri bolnikih, ki ne prenašajo teh zdravil, - orofaringealne kandidoze: kot terapija prve izbire pri bolnikih s hudo okužbo ali pri tistih z imunsko pomanjkljivostjo, pri katerih pričakujemo, da bo odziv na topikalno terapijo slab.
Do not take Posaconazole AHCL if you are pregnant unless you are told to by your doctor. 
Če ste noseči, ne jemljite zdravila Posakonazol AHCL, razen če vam to naroči zdravnik.
You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine. 
Posvetujte se tudi, če opazite neželeneučinke,kinisonavedeni v temnavodilu.Oneželenih učinkih lahko poročate tudi neposredno na nacionalni center za poročanje, ki je naveden vPrilogi V. S tem,koporočate o neželenihučinkih,lahkoprispevate k zagotovitvivečinformacij ovarnostitegazdravila.
Due to the risk of prolonged sedation and possible respiratory depression co-administration of posaconazole with any benzodiazepines metabolised by CYP3A4 (e.g. midazolam, triazolam, alprazolam) should only be considered if clearly necessary. 
Zaradi tveganja pojava dolgotrajne sedacije in morebitne depresije dihanja lahko sočasna uporaba posakonazola in katerega koli benzodiazepina, ki se presnavlja s CYP3A4 (npr. midazolam, triazolam,
If any of the above apply to you (or you are not sure), talk to your doctor, pharmacist or nurse before taking Posaconazole AHCL. 
Če kaj od naštetega velja za vas (ali če ste negotovi), se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro, preden začnete jemati zdravilo Posakonazol AHCL.
The absorption of posaconazole was significantly increased when posaconazole 400 mg (once daily) was administered during and immediately after the consumption of a high fat meal (~ 50 grams fat) compared to administration before a meal, with Cmax and AUC increasing by approximately 330 % and 360 %, respectively. 
Absorpcija posakonazola se je bistveno povečala, če so bolniki zaužili posakonazol v odmerku 400 mg(enkratnadan)obobroku z velikokoličinomaščob(~ 50 gramov maščobe) oziroma takoj potakšnem obroku, v primerjavi z jemanjemzdravila predobrokom.Pritemseje vrednostCmaxpovečalaza približno 330 %, vrednost AUC pa za približno 360%.
Other medicines and Posaconazole AHCL 
Druga zdravila in zdravilo Posakonazol AHCL
Titanium dioxide (E171) 
tekoča glukoza glicerol (E422) titanov dioksid (E171) aroma jagode (vsebuje propilenglikol)
If posaconazole is used concomitantly with CYP3A4 substrates that are administered orally, and for which an increase in plasma concentrations may be associated with unacceptable adverse reactions, plasma concentrations of the CYP3A4 substrate and/or adverse reactions should be closely monitored and the dose adjusted as needed. 
Med sočasno uporabo posakonazola in intravensko danih substratov CYP3A4 jepotrebna previdnost in po potrebi zmanjšanje odmerka substrata CYP3A4.Med sočasno uporabo posakonazola in peroralnih substratovCYP3A4, pri katerih lahko povečanjeplazemske koncentracijespremljajo nesprejemljivi neželeni učinki, jetreba skrbno spremljatiplazemske koncentracije substrata CYP3A4 in/ali neželene učinke in po potrebi prilagoditi odmerek zdravila.
What Posaconazole AHCL is and what it is used for 
Kaj je zdravilo Posakonazol AHCL in za kaj ga uporabljamo
Therefore, posaconazole may increase plasma concentration of digoxin and digoxin levels need to be monitored when initiating or discontinuing posaconazole treatment. 
Posakonazol torej lahko povečaplazemskokoncentracijodigoksina, zato je treba obuvedbi inpoprenehanju zdravljenjas posakonazolom spremljatikoncentracijo digoksina.
Co-administration of posaconazole with proton pump inhibitors should be avoided if possible. 
Sočasni uporabi posakonazola in zaviralcev protonske črpalke se jetreba izogibati, če je le mogoče.
Glucose concentrations decreased in some healthy volunteers when glipizide was co-administered with posaconazole. 
Med sočasno uporabo glipizida in posakonazola se je pri nekaterih zdravih prostovoljcih znižalakoncentracija glukoze.
Do not take Posaconazole AHCL if you are taking any of the following: - terfenadine (used to treat allergies) - astemizole (used to treat allergies) - cisapride (used to treat stomach problems) - pimozide (used to treat symptoms of Tourette's and mental illness) - halofantrine (used to treat malaria) - quinidine (used to treat abnormal heart rhythms). 
- terfenadin (za zdravljenje alergij) - astemizol (za zdravljenje alergij) - cisaprid (za zdravljenje težav z želodcem) - pimozid (za zdravljenje simptomov Tourettovega sindroma in duševnih bolezni) - halofantrin (za zdravljenje malarije)
If any of the above apply to you (or you are not sure), talk to your doctor or pharmacist before taking Posaconazole AHCL. 
Če kaj od naštetega velja za vas (ali če ste negotovi), se posvetujte z zdravnikom ali farmacevtom,preden začnete jemati zdravilo Posakonazol AHCL.
If you are not sure, talk to your doctor or pharmacist before taking Posaconazole AHCL. 
Če ste negotovi, se posvetujte z zdravnikom ali farmacevtom, preden vzamete zdraviloPosakonazol AHCL.
Posaconazole AHCL can be used in adults to treat the following types of fungal infections when other antifungal medicines have not worked or you have had to stop taking them: - infections caused by fungi of the Aspergillus family that have not improved during treatment with the anti-fungal medicines amphotericin B or itraconazole or when these medicines have had to be stopped; - infections caused by fungi of the Fusarium family that have not improved during treatment with amphotericin B or when amphotericin B has had to be stopped; - infections caused by fungi that cause the conditions known as “chromoblastomycosis” and “mycetoma” that have not improved during treatment with itraconazole or when itraconazole has had to be stopped; - infections caused by a fungus called Coccidioides that have not improved during treatment with one or more of amphotericin B, itraconazole or fluconazole or when these medicines have had to be stopped. 
- okužb,kijihpovzročajogliveiz družine Fusariumin ki se niso izboljšale med zdravljenjem zamfotericinom B, ali čejebilotreba amfotericin B ukiniti; - okužbzglivami,kipovzročajobolezni, imenovani"kromoblastomikoza"in "micetom",kiseniso izboljšale med zdravljenjem z itrakonazolom ali če jebilotreba zdravljenje zitrakonazolomukiniti; - okužb, ki jih povzročajo glive Coccidioides, ki se niso izboljšale med zdravljenjem z enim aliveč od naslednjih zdravil: amfotericinomB,itrakonazolomali flukonazolom,aliče jebilotrebazdravljenje s temi zdravilikončati;
In the fasting state, AUC increased less than in proportion to dose above 200 mg. 
Na tešče se je vrednost AUC povečalamanjkotbibilosorazmernoodmerkunad200 mg.
Each millilitre of oral suspension contains 40 milligrams of posaconazole. 
En ml peroralne suspenzije vsebuje 40 mg posakonazola.
During post-marketing surveillance of posaconazole oral suspension, severe hepatic injury with fatal outcome has been reported (see section 4.4). 
Bolezni jeter, žolčnika in žolčevodov Med spremljanjem v obdobju trženja peroralne suspenzije posakonazola so poročali o hudi okvari jeter s smrtnim izidom (glejte poglavje 4.4).
200 mg (5 mL) three times a day. 
Jemljite200 mg(eno polno 5 ml žličko) trikrat na dan.
H2 receptor antagonists and proton pump inhibitors Posaconazole plasma concentrations (Cmax and AUC) were reduced by 39 % when posaconazole was administered with cimetidine (400 mg twice a day) due to reduced absorption possibly secondary to a decrease in gastric acid production. 
Med sočasno uporabo posakonazola s cimetidinom(400 mg dvakrat na dan), so se plazemskekoncentracijeposakonazola (Cmaxin AUC)znižale za 39 % zaradi zmanjšaneabsorpcije verjetnozaradi zmanjšanega nastajanja želodčne kisline.
Posaconazole was not genotoxic in in vitro and in vivo studies. 
Posakonazol vštudijah invitro in invivo ni bil genotoksičen.
What Posaconazole AHCL looks like and contents of the pack Posaconazole AHCL is a white to off-white free flowing suspension, packaged in amber glass bottle. 
Posakonazol AHCLjebela do belkasta dobro tekoča suspenzija, pakirana v steklenički iz rjavega stekla.
11 of 16 patients were successfully treated (at the end of treatment complete or partial resolution of signs and symptoms present at baseline) with posaconazole oral suspension 800 mg/day in divided doses for a median of 296 days and up to 460 days. 
11 od 16 bolnikov so uspešno zdravili(ob koncu zdravljenja popolno alidelno izginotje izhodiščnihznakov in simptomov) s peroralno suspenzijo posakonazola 800 mg/dan v deljenih odmerkih.
As shown in Table 3, a successful response (complete or partial resolution) at the end of treatment was seen in 42 % of posaconazole-treated patients compared to 26 % of the external group. 
Kot prikazuje preglednica 3,jebil uspešen odziv(popolno alidelno izginotje) ob koncu zdravljenjaopazen pri 42 % bolnikov,zdravljenih s posakonazolom, in pri26 % bolnikov izzunanjeskupine.Vendarto ni bila prospektvina, randomizirana in kontrolirana študija,zatojetreba vse primerjave zzunanjo kontrolno skupino previdnoobravnavati.
- bleeding into your stomach or gut - signs include vomiting blood or passing blood in your stool - a blockage in your gut (intestinal obstruction) especially in the “ileum”. 
- krvavitev v želodec ali črevo - med znaki so bruhanje krvi ali kri v blatu
Elderly (≥ 65 years) An increase in Cmax (26 %) and AUC (29 %) was observed in elderly subjects (24 subjects ≥ 65 years of age) relative to younger subjects (24 subjects 18 - 45 years of age). 
Starostniki(≥65 let) Pristarostnikih (24 preiskovancev, starih ≥65let) so opažali povečanje Cmax(26 %)in vrednosti AUC(29
Rifamycin antibacterials (rifampicin, rifabutin), certain anticonvulsants (phenytoin, carbamazepine, phenobarbital, primidone), efavirenz and cimetidine 
Rifamicinski antibiotiki (rifampicin, rifabutin), določeni antikonvulzivi (fenitoin,
If concomitant administration is required, close monitoring for breakthrough fungal infections is recommended. 
Čejepotrebnasočasnauporaba,je bolnike priporočljivo skrbno spremljatigledeprebijajočihglivnih okužb.
Thereafter blood levels of ciclosporin should be monitored carefully during co-administration, and upon discontinuation of posaconazole treatment, and the dose of ciclosporin should be adjusted as necessary. 
Potem je treba natančno spremljati koncentracije ciklosporina v krvi, in sicermed sočasno uporabo inpoprenehanju zdravljenja s posakonazolom;odmerekciklosporina jetrebaprilagoditi,kotjepotrebno.